Abbvie Applies for EMA Marketing Authorization for Migraine Drug Atogepant
The drugmaker Abbvie has applied to the European Medicines Agency (EMA) for marketing authorization for Atogepant, its prophylactic migrain treatment. Data supporting the application comes from two phase three studies, which showed the drug was well tolerated and was effective at reducing the occurrence of migraines.
ICER Releases Final Report on Acute Treatments for Migraine
The Institute for Clinical and Economic Review (ICER) on Tuesday, Feb. 25, released its final report on three acute treatments [...]
ICER Hosts Meeting on Migraine Treatments
The Institute for Clinical and Economic Review (ICER) hosted a public meeting last week to discuss new treatments for migraines. [...]
Advertisement
